The number of active drug shortages has declined sharply since June, according to the FDA’s database.
As of March 19, 76 drugs are in shortage, down from 194 in mid-June.
The database is updated daily to reflect manufacturing recoveries, regulatory actions and how shortages are classified — not solely day-to-day availability at the hospital level.
Here are six recent drug shortages, according to the FDA database:
- Ursodiol capsules: Strides Pharma discontinued the 300 mg presentation as a business decision April 6.
- Idelalisib tablets: Gilead Sciences discontinued 100 mg and 150 mg Zydelig tablets due to manufacturing decisions April 7.
- Fosaprepitant dimeglumine injection: Fresenius Kabi discontinued the 150 mg/5 mL formulation April 8.
- Aprepitant oral powder for suspension: Merck discontinued the 125 mg Emend formulation, with discontinuation expected around November 2026.
- Azithromycin tablets: Pfizer discontinued 500 mg and 250 mg Zithromax tablets April 9.
- Nitrofurantoin oral suspension: Amneal Pharmaceuticals discontinued the 25 mg/5 mL formulation April 10.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
